Mielgo-Rubio Xabier, Martín Margarita, Remon Jordi, Higuera Oliver, Calvo Virginia, Jarabo José Ramón, Conde Esther, Luna Javier, Provencio Mariano, De Castro Javier, López-Ríos Fernando, Hernando-Trancho Florentino, Couñago Felipe
Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Budapest 1 Alcorcón, Madrid, 28922, Spain.
Department of Radiation Oncology, Ramón y Cajal University Hospital, M-607, km. 9, 100, Madrid, 28034, Spain.
Future Oncol. 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 Aug 2.
Lung cancer continues to be the leading cause of cancer mortality and a serious health problem despite the numerous advances made in the last decade and the rapid advance of research in this field. In recent years, there has been a decrease in mortality from lung cancer coinciding with the approval times of targeted therapy. To date, targeted therapy has been used in the context of advanced disease in clinical practice, with great benefits in survival and quality of life. The next step will be to incorporate targeted therapy into the treatment of earlier stages of non-small-cell lung cancer, and there is already a randomized trial showing a disease-free survival benefit. However, there are many questions that need to be resolved first. In the present review, the authors discuss the findings of published reports and ongoing clinical trials assessing the role of targeted therapies in nonmetastatic disease.
尽管在过去十年里取得了众多进展且该领域研究进展迅速，但肺癌仍然是癌症死亡的主要原因和严重的健康问题。近年来，肺癌死亡率有所下降，这与靶向治疗的获批时间相吻合。迄今为止，靶向治疗已在临床实践中用于晚期疾病，在生存和生活质量方面带来了巨大益处。下一步将是把靶向治疗纳入非小细胞肺癌早期阶段的治疗中，并且已经有一项随机试验显示出无病生存获益。然而，有许多问题需要首先得到解决。在本综述中，作者讨论了已发表报告和正在进行的临床试验的结果，这些试验评估了靶向治疗在非转移性疾病中的作用。
